Pacira BioSciences, Inc., a leader in non-opioid pain therapies, has announced promising preliminary data regarding its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), for osteoarthritis of the knee. The findings, presented at the American Society of Gene & Cell Therapy Annual Meeting, indicate that clinical immunogenicity does not diminish the sustained improvements in knee pain, stiffness, and function following local administration of PCRX-201. The study suggests that pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not affect the safety or effectiveness of the therapy. This development is part of Pacira's ongoing Phase 2 study and aligns with their 5x30 strategy for growth, aiming to provide long-lasting pain relief for the 14 million individuals affected by knee osteoarthritis. PCRX-201 previously received Regenerative Medicine Advanced Therapy designation from the FDA, and the new data supports its potential as an effective and durable treatment alternative to current short-term therapies.